Back to Search
FRANCISCO HERNANDEZ-ILIZALITURRI, MD
MD
Medical Oncology Physician
NPI: 1477559359IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
254445(NY)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
254445(NY)
Education
OTHER
Class of 1995
Research & Publications (20)
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.
PMID 19544696·Oncology (Williston Park)·2009
6-review
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies.
PMID 19626827·Oncology (Williston Park)·2009
6-review
Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
PMID 16263581·Leuk Lymphoma·2005
7-preclinical
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
PMID 16115943·Clin Cancer Res·2005
4-observational
Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
PMID 16163245·Clin Adv Hematol Oncol·2004
6-review
Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience.
PMID 14758136·Am J Clin Oncol·2004
8-other
Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
PMID 14676108·Clin Cancer Res·2003
7-preclinical
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
PMID 19147785·Blood·2009
7-preclinical
Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
PMID 19513947·Curr Opin Investig Drugs·2009
7-preclinical
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
PMID 18941114·Blood·2009
4-observational
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
PMID 17995965·Br J Haematol·2008
7-preclinical
Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
PMID 18071290·Bone Marrow Transplant·2008
3-trial
Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
PMID 18316580·Clin Cancer Res·2008
8-other
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
PMID 18316581·Clin Cancer Res·2008
8-other
Vascular endothelial growth factor polymorphisms in early-stage non-small-cell lung cancer.
PMID 18591568·J Clin Oncol·2008
8-other
Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
PMID 17671142·Clin Cancer Res·2007
7-preclinical
CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
PMID 18067019·Leuk Lymphoma·2007
8-other
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
PMID 16507269·J Natl Compr Canc Netw·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- ELM AND CARLTON ST
BUFFALO, NY 14263 - Phone
- (716) 845-2300
Quick Facts
- NPI
- 1477559359
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 31
- Publications
- 20
Are you this provider?
Claim Your Profile